【4565】そーせいG 443 【SOSEI平成30年3月期決算発表：5/10】
レス数が1000を超えています。これ以上書き込みはできません。
・・・
※ロイターレポート更新：(4/29up)
・SOSEI通期業績予想コンセンサス(4/27更新)：売上高8,767百万円、営業利益__903百万円、経常利益-1,912百万円、当期利益-1,818百万円。ロイター指標株価---円。
※Heptares: We are currently seeking an experienced "Molecular Biologist" to join the protein engineering group working on GPCR structure determination to enable drug discovery efforts. (4/29 Closed)
Heptares Events update:
※Swiss Biotech Day 2018: Basel, Switzerland, 3 May 2018.
・13:30, Emerging Biotech Companies Presentations: "Heptares Therapeutics Zurich Ltd., Carlo Bertozzi (Director of Operations)." (※4/28update)
※Biotech Outsourcing Strategies 2018: Basel, Switzerland, 19-20 June 2018. (※4/27up)
・Attending-Companies: Heptares Therapeutics (CMC Projects Manager).
・・・ ・・・
※Reuters Analysts Forecasts: Ultibro 2017FY(400m: +10.19%), Ultibro 2018FY(466m), Ultibro 2019FY(509m), Seebri 2017FY(149m: 0%), Seebri 2018FY(151m) , Seebri 2019FY(154m). (2017/10/19update)
※SOSEI：ウルティブロへ治療薬切り替え後のCOPD患者肺機能を有意に改善。Seretideから切り替えで肺機能が改善し、良好な忍容性を有する新データ(FLASH)が得られた。(2017/11/28)
※中国COPD新薬市場の進展：Ultibro Breezhaler、2017年5月に中国で上市申請を行い、2018年には中国市場に参入予定。来年後半以降、COPD市場全体に新たな変化が起こることが予想されます。(2017/12/8)
※中国COPDインダカテロール/グリコピロニウム化合物：輸入申請はCFDA薬物登録の進捗状況が｢承認時｣に変更、国内レビューおよび承認作業の完成に近づいています。(2017/12/12)
※ClinicalTrials: Ultibro(Phase3): "Concept2 Inhaler: Digital Adherence System": Evaluate the Effect of Reminder Notifications and Motivational/Adaptive Messaging: "Study Start: 2018/3/23" (2017/12/20up)
※ClinicalTrials: Phase 3, Study to Compare QVM149 and Free Triple Combination (salmeterol/ fluticasone+ tiotropium): Change, Start Date: "2018/1/15"(11/22update), Participants: 1251→"1500". (2017/12/20update)
※Vectura Presentation: Ultibro Q3 net sales, up 18% in Europe. Strong growth with FLAME data supporting strong, Ultibro evolution. QVM149 First regulatory submissions expected in 2019. (1/4)
※Ultibroは正式承認(12/28)。中国で最初に承認された二重拡張薬になる。Ultibro承認の良いニュースは中国COPD患者治療に新たな希望をもたらした。2018年に中国のCOPD治療領域が前進します！(1/9)
※ClinicalTrials: Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared: "Add Locations: Germany", "Change, Study Completion: 2018/4/26" (1/15update)
※Novartis Q4 & FY 2017 Results: Ultibro(China; Approved in December 2017): Q4 (120million, +26%cc), 2017FY (411million, +12%cc), Seebri: Q4 (42million, +4%cc), 2017FY (151million, +3%cc). (1/24)
※Novartis Annual Report 2017: "Ultibro, A New Version of the Breezhaler Device is being Developed that contains electronics. The First Clinical Study(12/20up) with this Inhaler is due to begin this Year in COPD." (1/24) ※SOSEI：｢シーブリおよびウルティブロ｣の2017年第4四半期(10月〜12月)の業績について。サノビオン社(10月にSeebri Neohaler販売開始)。｢ウルティブロ｣中国(12月に製造販売承認を取得)。(1/24)
※Australian Government, TGA Annual Summary 2017: Registrations of Extended Uses of Already-Approved Prescription Medicines: "September 2017, Ultibro Breezhaler" (1/29up)
※大日本住友製薬第3四半期決算：北米COPD新製品群2017年度3Q実績3百万ドル(4億円)円ベース進捗率54.4%、2017年度通期予想6百万ドル(7億円)。(1/30)
※ATS(5/21), ITEM Scientists will Present: "CLAIM study: Lung deflation and improvement of cardiac end-diastolic volumes with IND/GLY reduce dyspnea and improve health status in hyperinflated COPD patients". (2/3up)
※ClinicalTrials: Phase 3, Study to Compare QVM149 and Free Triple Combination(sal/ flu+ tio): Change, Study Start: 2018/1/15→"2018/2/5", Primary Completion: 2019/3/29→"2019/6/21". (2/6update)
※ClinicalTrials: Phase 2 (NVA237 Asthma), Bronchodilator Effects and Safety of NVA237 (25 ug and 50 ug o.d.) in Asthma. Status Change: "Completed" (2018/4/16[Anticipated]→"2017/12/29"[Actual])". (2/15update)
※Lancet Respiratory Medicine: "Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM)". (2/21)
※SOSEI：ウルティブロブリーズヘラー投与治療により肺過膨張を伴うCOPD罹患患者の心臓機能及び肺機能が大幅に改善。2剤配合気管支拡張薬が心臓機能へ与える影響を調査した初めての試験(CLAIM)。(2/22)
※ClinicalTrial: Phase 2, Two Doses of QVM149 Compared to a Fixed Dose Combination of Sal/Flu in Patients with Asthma. Status Change: "Recruiting", Actual Start: "2017/5/31", Completion: "2018/8/2". (3/2update)
※ClinicalTrial: Phase 2, Two Doses of QVM149 Compared to a Fixed Dose Combination of Sal/Flu in Patients with Asthma. Patients who have used ICS and LABA combinations for asthma for at least "1 year".→"3 month". (3/6update)
※ClinicalTrial: Phase 3, Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients with Asthma. Change: Study Start"2015/2/1"[Actual], Completion "2019/6/3"[Anticipated]. (3/7update)
※ClinicalTrial: Phase 3, A Multicenter, Open-label, Single Arm, 52-week Treatment Study to Assess the Safety of QVM149 in Japanese Patients with Asthma. Primary Completion[Anticipated]: 2018/11/6→"2018/9/18". (3/9update) ※ClinicalTrial: Phase 3, Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium. Status Change:"Recruiting", Actual Study Start: "2018/2/9" (3/12update)
※Vectura 2017 Preliminary Results: Ultibro and Seebri, 2017 combined net sales of $562 million and Vectura recognised € 17.3 million of Total Royalties for sales of these products. (3/21)
※Vectura Earnings Call: "Ultibro growing at almost 21% year-on-year.", "In our 2018 outlook strong growth of revenues driven by Ultibro in particular." (3/21)
※Sunovion: Utibron and Seebri, Savings Card (Savings Program: Valid for up to $250 off; cost may be as little as a $0 Co-Pay; qualify for a 30-Day Trial Offer): Expiration: 2018/3/31→"2019/3/31". (4/1update )
※ClinicalTrial: Phase 3, Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium. Actual Study Start: "2018/2/5". Locations Added: "Argentina, Turkey". (4/4update)
※Journal of COPD: "Exacerbation heterogeneity in COPD: Subgroup analyses from the FLAME study". (4/10)
※Journal of COPD: "IND/GLY reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL Study". (4/16)
※Novartis Q1 2018 Results: "Ultibro (USD 106 million, USD +16%, +4% cc)" continued to grow. "Seebri (USD 38 million, USD +11%, -4% cc)" declined due in part to a focus of resources on Ultibro. (4/19)
※SOSEI：｢シーブリおよびウルティブロ｣の2018年第1四半期(月〜3月)の業績について (4/20)
・ウルティブロは、FLAME, FLASH, CLAIM Studyの良好な結果、並びに2018年版GOLDレポートに後押しされ、引き続き進捗しました。。シーブリは「ウルティブロ」への注力に伴い、減少しました。
※Sosei Statement：英Vecturaに対して買収提案を実施した可能性に関する報道を受けましたが、当社はVecturaに対して買収提案を実施した事実はございません。本件に関して検討している事実はありません。(4/25)
・・・
※大日本住友製薬 2018年3月期決算発表：(5月11日)
※ATS 2018: "Lung deflation and improvement of cardiac end-diastolic volumes with IND/GLY reduce dyspnea and improve health status in hyperinflated COPD patients: the CLAIM study" (5/21 14:15 Presenting)
・・・ 買収でのし上がってきた会社の買収を無能買収とはね
買収してなかったらウルシーの権利もヘプタレスも無いんだけどね >>961
それなんだよな
買収に関しては、マジで天才的なんだわ ウリシーもスター技術もジツボもAPNTも全部買収だからな！
自前なのはノルレボとカンジダだけｗ 俺の12000円100株助かるの？
信用でナンピンしようかなー >>963
というか、ガンジタの承認そろそろじゃないか？
もう申請してそれなりにたったよな 俺は、目黒星美に通っていない、聖学院にも通っていない。
俺は、東海大学付属望星高校にも、ルネサンス高校にも、通っていない。
悪い学校に通う理由が無い。 ※Pluristem: U.S. FDA Clears Pluristem’s IND to Treat Victims Exposed to Acute Radiation. (4/30)
HAIFA, Israel, April 30, 2018 –
Pluristem Therapeutics Inc. (PSTI), a leading developer of placenta-based cell therapy products,
announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for its PLX-R18 cell therapy in the treatment of acute radiation syndrome (ARS).
The IND allows Pluristem to treat victims who may have been acutely exposed to high dose radiation due to nuclear attack or accident.
With this IND in place, Pluristem will now start the necessary preparations in order to keep an emergency stock of PLX-R18 on hand for use in such events.
The U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) sponsored and completed a successful Phase II-equivalent study of PLX-R18 in the treatment of ARS via the FDA’s animal rule pathway.
PLX-R18 is also being studied by the U.S. Department of Defense (DOD) to support the needs of the armed forces and study PLX-R18 as a treatment prior to, or within the first 24 hours of, radiation exposure.
Pluristem is currently in discussions with the FDA and several U.S. governmental agencies to clear the path for its proposed pivotal study of PLX-R18 in ARS.
Per the IND protocol, PLX-R18 will be provided up to 96 hours following radiation exposure.
The approved dosage for treatment in humans is 4 million cells per kilogram, the optimal dosage that was determined in the Phase II-equivalent non-human primate pilot study.
PLX-R18 cells demonstrated a dramatic increase in survival of population exposed to high dose of radiation and enhancement of blood lineages recovery.
“We are proud to have PLX-R18 join the exclusive club of IND approved medical countermeasures for the treatment of ARS.
This FDA clearance is one of the most significant milestones in the development of PLX-R18 to date and should provide Pluristem with significant support in advancing its off-the-shelf cell therapy into a pivotal trial.
The fact that we are now able to treat human casualties in the case of a nuclear event provides us with the ability to protect from severe health consequences, saving lives of population in need,”
stated Pluristem Chairman and Co-CEO Zami Aberman. もう製薬会社が儲からない社会になってきてるんじゃないの？
ジェネリックの使用率はアメリカで90％、イギリスで80％、日本で70％だしなあ。
そのうち延命より、安楽死にシフトしていくんじゃないのか？ もう二度と一万いく気しないんだがどうすりゃええのんや ※Pluristem 1時間前：FDA clears Pluristem radiation treatment for emergency use. (4/30)
・This clearance is a major vote of trust in Pluristem’s product and of course provides the company with the ability to protect from severe health consequences, saving lives of population in need.
↓
※Reuters: FDA clears Pluristem radiation treatment for emergency use.
HAIFA, Israel (Reuters) APRIL 30, 2018
Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug Administration has cleared the emergency use of its therapy to treat acute radiation exposure in a nuclear event.
Pluristem said it will start preparations to keep an emergency stock of PLX-R18 on hand for use in such events.
Full approval of the drug will depend on the results of a Phase III clinical trial. Pluristem said on Monday it is in discussions with the FDA and several U.S. agencies to clear the path for such a large final-stage study.
The U.S. National Institutes of Health’s National Institute of Allergy and Infectious Diseases sponsored and completed a mid-stage study of PLX-R18 in the treatment of acute radiation syndrome (ARS) in animals via the FDA’s “animal rule pathway”
as ARS cannot be tested in humans. PLX-R18 will be provided up to 96 hours following radiation exposure.
It is also being studied by the U.S. Department of Defense to support the armed forces as a treatment prior to, or within the first 24 hours of radiation exposure.
“We are increasing the survival rate following high-level radiation exposure,” Arik Eisenkraft, Pluristem’s director of homeland defense projects, told Reuters.
“We see improvement in all three blood lineages - red cells, white cells and platelets.” PLX-R18 is injected into the muscle twice, a week apart.
It is designed to treat bone marrow that is unable to produce enough blood cells due to a variety of causes, including ARS and certain cancers or cancer treatments.
“We think that the everyday use of the compound will be for bone marrow failure of any cause,” Eisenkraft said.
Pluristem said its cells can be administered to patients without the need for tissue matching. One placenta makes 20,000 treatments.
Pluristem is conducting advanced Phase III trials in the United States and Europe of another product, PLX-PAD, to treat patients with the end-stage of peripheral artery disease, to prevent the need for amputation.
“In Europe, we are hoping to open data at the end of 2019 and in the U.S. a year later,” co-CEO Zami Aberman said.
That treatment has also been approved for a Phase III trial, to begin in the next few months, in patients with the most common form of hip fracture, in which the cells are injected during surgery, he said. ・・・
※SOSEI：MiNA社に対する3,500万英ポンド投資(25.6%株式取得)および同社買収オプション権(全株式取得)を含む投資契約の締結：プラットフォーム技術の補完、戦略M&Aによる成長戦略。(2017/5/3)
・OUTREACHの結果による段階的な条件付対価体系。"OUTREACHフェーズ1／2a臨床試験からの重要臨床データは、2018年中に明らかになる見込です。"
※SOSEI決算説明会：MiNA社買収のオプション権を含む投資契約：そーせいグループのパイプライン開発の加速並びに拡大、目覚ましく拡張した技術プラットフォームを創出。新たな基盤技術獲得の可能性。(2017/5/12)
：直近12-18 ヶ月の見通し：MiNA：パイプラインがPh2b/3臨床試験へと進展。(MTL-CEBPA 進行性肝がん(HCC)を適用としたPh1/2aの臨床データ読み出し：Ph2b/3へと開発が進捗。)
・その他の適用でMTL-CEBPAのPh1/2a臨床試験が開始。・その他のsaRNAターゲットにおける前臨床試験が開始。
※ClinicalTrials: Phase 1/2a, First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH): "Add, 2a Protocol". (2017/5/24 update)
※ClinicalTrials: First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer: Primary Completion: 2017-09→"2018-09" Study Completion: 2017-12→"2018-12". (2017/6/14update)
※SOSEI (English)：Presentation Material as of July 2017: "For Further Growth.", "Potential to have Two Discovery Engines: StaR & SBDD (Heptares), saRNA Therapeutics (MiNA)". (2017/7/5)
・saRNA Technology offers potential for new discovery engine: RNAa represents a platform technology that can rapidly generate a portfolio of programs: "12 months from target selection to development candidate".
※MiNA Therapeutics: Announces Publication of Pre-Clinical Data Supporting On-Target Mechanism of Action of Clinical Candidate MTL-CEBPA. (2017/9/6)
※MiNA Therapeutics: MiNA Research Team at OTS2017. "MTL-CEBPA has Efficacy in a Broad Range of Liver Disease Models and Encouraging Early Clinical Data in a Phase 1 Trial in HCC." (2017/9/22)
※MiNA Therapeutics: Seeking a Senior Research Scientist to join its Research Team Developing Novel Therapeutics. (2017/10/14 Closed)
※MiNA Therapeutics: Seeking a Research Technician/Laboratory Manager to Join Its Research Team Developing Novel Therapeutics. (2017/10/15 Closed)
※MiNA Therapeutics: MiNA Research Featured as a HOT PAPER by OTS. Best Ones to Highlight Them! "Novel Therapeutic in Clinical Trials for Liver Cancer." (2017/10/23)
※MiNA Therapeutics: Innovate UK Awards Grant to "MiNA" and "LGC LINK": Exciting New Area of Research in Collaboration. Grant of up to Approximately £400,000 will Support a Two-Year. (2017/11/2) ※MiNA Therapeutics: Boehringer Ingelheim and MiNA Therapeutics to Develop Novel Treatment Approaches for Fibrotic Liver Diseases. (2017/11/8)
・"This collaboration is a recognition of our platform and expertise in liver-based diseases as well as validation from an established pharmaceutical leader in what has been an exciting year for the company."
・"This new collaboration is another sign of our ongoing commitment to patients with cardio-metabolic diseases, including NASH."
・"It will combine MiNA’s pioneering work with saRNAs with our expertise in biopharmaceutical research and development."
※SOSEI：MiNA社、Boehringer Ingelheim社と線維性肝疾患の新治療法開発でライセンス契約締結。契約一時金や研究資金に加え、最大総額307百万ユーロのマイルストンを受領予定。(2017/11/8)
・さらに、MiNA社は、共同研究開発により開発された医薬品全ての販売高に応じて二桁パーセントのロイヤルティを受領する権利を有します。
※SOSEI第2四半期決算説明資料：経営資源の最適な配分を実現する戦略的フレームワーク：価値最大化の最適な実現に向けて。ビジネスハイライト：オペレーション及び経営戦略上の重要な進捗を複数実現。(2017/11/9)
・MiNA社への戦略的な投資により、将来性の高いRNA治療薬領域に参入：Boehringer Ingelheim社との提携は、MiNA社が有するsaRNA技術の高い可能性を立証。
・MiNA：提携契約・ライセンス契約をBI社と締結。MiNA社は契約一時金や研究開発資金並びに、マイルストンで最大307百万ユーロを受領する予定。(New)
※米国特許出願(MiNA)：Albumin Production and Cell Proliferation. (11/9公開)
※MiNA Therapeutics: "Development and Mechanism of Small Activating RNA Targeting CEBPA, a Novel Therapeutic in Clinical Trials for Liver Cancer" (2017/12/1up)
※SOSEI (English) Presentation Material: (J.P. Morgan Healthcare Conference: 1/8): ttp://v4.eir-parts.net/v4Contents/View.aspx?template=ir_material_for_fiscal_ym&sid=44192&code=4565 (1/16up)
・Strategic investment in saRNA therapeutics with lead candidate in Phase 1/2a for liver cancer, an orphan indication
・We are excited about the potential of saRNA therapeutics. MiNA’s recent deal with Boehringer Ingelheim further supports MiNA/saRNA’s potential.
※米国特許(MiNA)：Methods of Inducing Insulin Production. (2/6公開) ※RNA Therapeutics Conference, London: "Utilising Small Activating RNA (saRNA) for Therapeutic Opportunities": Nagy Habib, Chairman and Co-Founder, MiNA Therapeutics. Attend: Heptares. (2/21)
※欧州特許出願(MiNA)：Sarna Compositions and Methods of Use. (2/28公開)
※欧州特許出願(MiNA)：C/EBP Alpha Sarna Compositions and Methods of Use. (2/28公開)
※MiNA Therapeutics: Read about Our CEO Robert Habib in an Interview with OTS (Oligonucleotide Therapeutics Society). (3/2)
※MiNA Therapeutics: Small Step Up to 1st Floor at the Translation & Innovation Hub (Imperial College London White City Campus). (3/8)
※MiNA Therapeutics: Announces Publication of Pre-Clinical Data Supporting Therapeutic Potential of Clinical Candidate MTL-CEBPA in Liver Cancer and Liver Disease. (3/9)
※MiNA Therapeutics: New Lab Equipment alert: Liquid Nitrogen Storage for when -80C just doesn't cut it. (3/27)
※MiNA Therapeutics: Tissue culture. Class II Cabinets fired up for action. (4/10)
※米国特許(MiNA)：Albumin production and cell proliferation. (4/17公開)
※MiNA Therapeutics: Seeking two highly motivated and talented "Senior Technicians" to join its research team developing novel therapeutics in the field of RNA activation. (4/17Closed)
※米国特許出願(MiNA)："Methods of Inducing Insulin Production." (4/26公開)
・・・
※TIDES: Oligonucleotide and Peptide Therapeutics 2018: "RNA Activation in NASH, Liver Failure and Hepatocellular Carcinoma": Nagy Habib, MiNA Therapeutics. (5/10 10:45)
※ASGCT: "Short Activating RNAs. MTL-CEBPa has a Broad Range of Liver Disease Models and Encouraging Early Clinical Data in a Phase 1 Trial in HCC": Nagy Habib, MiNA Therapeutics. (5/18 9:00)
・・・ ※SOSEI： Heptares社、GPCRをターゲットとした独自の構造ベース創薬の促進と拡大を目指し、協力的な研究開発イニシアチブであるORBIT開始。(2016/2/2)
・この新たなイニシアチブにおける最初の取り組みとして、インペリアル・カレッジ・ロンドンのNationalHeart and Lung Institute(NHLI)の研究者と共に、
・喘息や炎症性腸疾患を含む幅広い免疫性疾患に関連するオーファン受容体に注力していきます。
・・・
※Imperial College London: Imperial partners with Heptares to search for new gut drugs. "to Rapidly Advance Drug Discovery and Translational Research" (1/10)
※SOSEI：Heptares社、インペリアル･カレッジ・ロンドンとGPCRに関連した消化器疾患治療薬の研究開発を目的とした共同研究開発契約を締結。(1/11up)
・Heptares社は、本提携の結果得られた化合物に関する開発の進捗および商業化の責任を負います。また、この提携では、当社およびHeptares社で実施中の創薬および開発プログラムの支援も行います。
※Imperial College London: Recruit a "Research Associate" to join the research programme in Imperial Heptares project, which focuses on the "Role of GPCRs in gastrointestinal physiology". (3/14Closed)
※Imperial College London Faculty of Medicine: Research Projects: "Project Title: Exploring the physiology of colonic nutrient sensing and neuroendocrine signalling" (4/6up)
・Dissecting the complex interactions between metabolites and their target receptor(s) will provide a novel strategy for better understanding GI GPCR pharmacology.
・This project builds on recent work from Professor Frost and Professor Ed Tate, Professor of Chemical Biology at Imperial College.
・"The proposal will also involve Dr Alastair Brown at Heptares, who are developing a strategic collaboration with the college which cuts across gastrointestinal physiology."
※Imperial College London: We are seeking a Post-Doctoral Scientist "Research Associate" with a background in engineering or physical sciences. Heptares Partnership Project. (4/17Closed)
※Imperial College London: MRC iCASE Doctoral Training Programme: "Project (Heptares also involved): Exploring the physiology of colonic nutrient sensing and neuroendocrine signalling" (4/26 Closed)
・・・ ・・・
Events:
※Swiss Biotech Day 2018: Basel, Switzerland, 3 May 2018.
・May 3, 13:30, Emerging Biotech Companies Presentations: "Heptares Therapeutics Zurich Ltd., Carlo Bertozzi (Director of Operations)."
※TIDES: Oligonucleotide and Peptide Therapeutics 2018: Boston, MA, USA, May 7-10, 2018.
・May 10, 10:45-11:15, mRNA, CRISPR and Hot Topics in Oligonucleotides: "RNA Activation in NASH, Liver Failure and Hepatocellular Carcinoma": Nagy Habib, MD Head of R&D, MiNA Therapeutics.
※World Advanced Therapies & Regenerative Medicine Congress: London, May 16 - 18 2018.
・May 17, 14:50, "Engineering cell therapeutics for controlled drug delivery - clinical case studies": Zami Aberman, Chairman and Chief Executive Officer, Pluristem.
・May 17, 15:10 , "Placental derived cell for allogeneic treatment of solid cancer": Zami Aberman, Chairman and Chief Executive Officer, Pluristem.
※ASGCT 21st Annual Meeting: Chicago, IL, 16-19 May 2018.
・May 18, 9:00, "Short Activating RNAs. MTL-CEBPa has a Broad Range of Liver Disease Models and Encouraging Early Clinical Data in a Phase 1 Trial in HCC.": Nagy Habib (MiNA Therapeutics), Imperial College of London.
※ATS(American Thoracic Society) International Conference 2018: San Diego, CA USA, May 18-23 2018.
・May 21, 14:15, "Lung deflation and improvement of cardiac end-diastolic volumes with indacaterol/glycopyrronium reduce dyspnea and improve health status in hyperinflated COPD patients: the CLAIM study": Jens Hohlfeld. ※ASCO Annual Meeting: Chicago, IL, 1-5 June 2018.
・MiNA Therapeutics.
※The BIO International Convention 2018: Boston, MA, June 4-7, 2018.
・Yaky Yanay, President & Co-CEO, Pluristem.
※NovAlix Biophysics in Drug Discovery 2018: Boston, MA, USA, Jun 13-15, 2018
・June 14, 15:10, "Structural Insight into Allosteric Modulation of GPCRs": Dr Miles Congreve (Heptares)
※23rd Annual Congress of EHA (European Hematology Association): Stockholm, Sweden, 14-17 June 2018.
・MiNA Therapeutics.
※7th LSX CEO Forum (formerly Biotech and Money CEO Forum), London: 28 June 2018.
・14:15, Case Studies and Peer Review: "Sosei - AZ immune-oncology collaboration" - Malcolm Weir, Chief R&D officer, Sosei (former CEO Heptares) (Invited).
※Adrenoreceptors 2018, Receptor Structure Changes the Pharmacology Paradigm: Shizuoka, Japan, Jun 28-30, 2018
・Jun 28, "Structural insight driving commercial drug discovery": Rob Cooke (Heptares) >>975
マジレスするなら一旦切ったら？
時間かければ戻ると思うけどすぐに出そうなポジティブなネタ思いつかないし、仮にでても外資の押さえつけを振り払うの大変だし。 ※18th World Congress of Basic and Clinical Pharmacology (WCP2018) Kyoto, Japan: July 1- 6, 2018.
・July 6, 10:20, "Biased apelin receptor agonists for cardiovascular disease" :Anthony P. Davenport, University of Cambridge, UK, (Heptares ORBIT Projects)
※日本核酸医薬学会 第４回年会, 博多, 日本：2018年7月9日〜11日.
・MiNA Therapeutics.
※Early Career Scientist Forum on GPCR Signal Transduction (ECSF-GPCR): Berlin, Germany, Jul 11-14, 2018
・Ali Jazayeri (Heptares)
※Biotech Outsourcing Strategies 2018: Basel, Switzerland, 19-20 June 2018.
・Attending-Companies: Heptares Therapeutics (CMC Projects Manager).
※2018 Medicinal Chemistry GRC(Gordon Research Conference): Treatment of Cancer: Recent Medicinal Chemistry Advances: NH, US: August 5 - 10, 2018.
・2018 Medicinal Chemistry GRC Contributors: Heptares Therapeutics.
・August 6, 9:45-10:15, "Novel Adenosine 2A Receptor Antagonist AZD4635: From the Brain to the Tumor Microenvironment": Michelle Lamb (AstraZeneca, USA).
※7th SCI/RSC Symposium on GPCRs in Medicinal Chemistry, Verona, Italy: September 10-12, 2018.
・Sep 11, 9:30 "Keynote: Application of structure-based drug design to peptidergic GPCRs": Miles Congreve, Heptares Therapeutics.
・Sep 12, 9:00 "Keynote: Shedding light on G protein bias: structures of GPCRs coupled to G proteins determined by cryo-EM and X-ray crystallography": Chris Tate, MRC LMB.
・・・ 557
ian***** 強く買いたい5月1日 02:35
Allrganの2018、第1期の発表があった、その中例によって小生の早とちりで無ければ良いのですが、吟味していないが
そーせいとの提携の中止が発表されたようだ。今のAllegan社の経営内容では巨額な資金と時間を要するMしりーずの
開発は困難でそーせいに返却されるようだ。Allegan社の今後の開発にMしりーずがんっていない。副作用があっても上
市が早い痴呆改善薬製、と偏頭痛薬、双極性の躁鬱病薬、兎に角黒字化を急ぐため､早期に上市できる製品に集中した
ようだ。Teva社と同じようなものだ。
さて、今後のそーせい､Heptaresの動向はどうなるのか。経営陣の手腕が試される時となってきた。
ここである論文を紹介しておきます。4月30日付けの論文です。Vantageの2018年4月30日付けの論文です。
Sosei deal marks Allergan’s return to business as usual
Date April 07, 2016
Anyone who thought it would take Allergan a while to find its feet got a shock today when, just one day after its $160bn
acquisition by Pfizer fell apart, the group went back to business to strike a generous-looking phase I deal with Sosei。
・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・・
アラガンがMシリーズ開発中止&そーせいに返却らしいぞ
こりゃS安だな アラガンプレゼンにもニュースでも出てないけど、これほんと？
「吟味してない」とか予防線は貼ってるけど、嘘だったらアウトだろ。これ。 どうせやる気なくて二年間進めてなかったんだしまた130億円で買ってもらえばいいじゃん あほやな
アラガンは成功確率上げるために時間かけてるだけやのに どうしても欲しくなっちゃったんだろ
これはやったらアカンやつやな どうせ馬鹿だから本当なら返還されましたって書いて暴落するよ 米国株式市場は下落、ヘルスケア株の下げ響く 月間では小幅上昇 ロイター Ｓ＆Ｐヘルスケア株.SPXHCは１．６％安。アイルランドの製薬大手アラガン(AGN.N)と米バイオ医薬品のセルジーン(CELG.O)の下げが響いた。
ロイター これといった謝罪も断言も掲載せず、やっぱり場が開くまで引き伸ばそうとしてるね このスレッドは１０００を超えました。
新しいスレッドを立ててください。
life time: 10日 17時間 14分 58秒 5ちゃんねるの運営はプレミアム会員の皆さまに支えられています。
運営にご協力お願いいたします。
───────────────────
《プレミアム会員の主な特典》
★ 5ちゃんねる専用ブラウザからの広告除去
★ 5ちゃんねるの過去ログを取得
★ 書き込み規制の緩和
───────────────────
会員登録には個人情報は一切必要ありません。
月300円から匿名でご購入いただけます。
▼ プレミアム会員登録はこちら ▼
https://premium.5ch.net/
▼ 浪人ログインはこちら ▼
https://login.5ch.net/login.php レス数が1000を超えています。これ以上書き込みはできません。
